This remarkable expansion is driven by multiple converging factors across the pharmaceutical and healthcare landscape
#CaringforLife #CiplaAt90 #HealthcareAccess #Yurpeak #Tirzepatide #DiabetesManagement #ObesityTreatment Cipla launches Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) two of the countrys most pressing health challenges
Additional research areas include Epithalon's effects on gene expression patterns associated with aging
Why Choose Our Case
Available from: Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC, et al
33 In a human in vitro airway model, repeated DHA aerosol exposure for 5 weeks (mimicking spray tanning behavior) transiently and irreversibly reduced ciliary beating frequency and mucin secretion, while the barrier function was maintained and no apoptosis occurred